NCT04594811 - NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

May 26, 2023

Study Completion Date

May 26, 2023

Conditions

Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)

Interventions

DRUG

NT-I7

Administered by intramuscular (IM) injection.

DRUG

Nivolumab

Administered by intravenous (IV) injection.

Trial Locations (6)

University of Louisville James Graham Brown Cancer Center, Louisville

University of Michigan, Ann Arbor

The Center for Cancer & Blood Disorders, Fort Worth

The University of Texas MD Anderson Cancer Center, Houston

Centrum Medyczne Klara, Częstochowa

Pratia Poznań, Skorzewo